This project aims to educate the public about the lack
of evidence to support screening the general population for
prostate cancer by using blood tests. Simply looking at the
financial cost of such screening, one can easily see the great
expense in adding just one year to one person’s life. Further
review would demonstrate such screening not only is very
expensive, but many times causes more harm than good. In a time
of great financial difficulty in the United States, it is crucial
that the health care industry uses screening techniques that are
proven to be cost effective (and improve health outcomes).
Prostate specific antigen (PSA) screening is not a useful tool in screening the general population for prostate cancer.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.